Literature DB >> 24563469

Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis.

Candida Cristina Quarta1, Scott D Solomon, Imran Uraizee, Jenna Kruger, Simone Longhi, Marinella Ferlito, Christian Gagliardi, Agnese Milandri, Claudio Rapezzi, Rodney H Falk.   

Abstract

BACKGROUND: Immunoglobulin amyloid light-chain (AL)-related cardiac amyloidosis (CA) has a worse prognosis than either wild-type (ATTRwt) or mutant (ATTRm) transthyretin (TTR) CA. Detailed echocardiographic studies have been performed in AL amyloidosis but not in TTR amyloidosis and might give insight into this difference. We assessed cardiac structure and function and outcome in a large population of patients with CA and compared findings in TTR and AL-related disease. METHODS AND
RESULTS: We analyzed 172 patients with CA (AL amyloidosis, n=80; ATTRm, n=36; ATTRwt, n=56) by standard echocardiography and 2-dimensional speckle-tracking imaging-derived left ventricular (LV) longitudinal (LS), radial, and circumferential strains. Despite a preserved LV ejection fraction (55±12%), LS was severely impaired in CA. Standard measures of LV function and speckle-tracking imaging worsened as wall thickness increased, whereas apical LS was preserved regardless of the pathogenesis of CA and the degree of wall thickening. Compared with ATTRm and AL amyloidosis, ATTRwt was characterized by greater LV wall thickness and lower ejection fraction. LS was more depressed in both ATTRwt and AL amyloidosis (-11±3% and -12±4%, respectively, P=0.54) than in ATTRm (-15±4%, P<0.01 versus AL amyloidosis and ATTRwt). TTR-related causes were favorable predictors of survival, whereas LS and advanced New York Heart Association class were negative predictors.
CONCLUSIONS: In patients with CA, worsening LV function correlated with increasing wall thickness regardless of pathogenesis. Patients with ATTRwt had a statistically greater wall thickness but lesser mortality than those with AL amyloidosis, despite very similar degrees of LS impairment. This paradox suggests an additional mechanism for LV dysfunction in AL amyloidosis, such as previously demonstrated light-chain toxicity.

Entities:  

Keywords:  amyloid; amyloidosis, hereditary, transthyretin-related; cardiomyopathies; echocardiography; transthyretin

Mesh:

Substances:

Year:  2014        PMID: 24563469     DOI: 10.1161/CIRCULATIONAHA.113.006242

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  81 in total

1.  Predictors of survival stratification in patients with wild-type cardiac amyloidosis.

Authors:  F Aus dem Siepen; R Bauer; A Voss; S Hein; M Aurich; J Riffel; D Mereles; C Röcken; S J Buss; H A Katus; Arnt V Kristen
Journal:  Clin Res Cardiol       Date:  2017-09-27       Impact factor: 5.460

2.  Role of echocardiography in assessing cardiac amyloidoses: a systematic review.

Authors:  Jun Koyama; Masatoshi Minamisawa; Yoshiki Sekijima; Koichiro Kuwahara; Tsutomu Katsuyama; Kazutoshi Maruyama
Journal:  J Echocardiogr       Date:  2019-02-11

Review 3.  Echocardiographic Findings in Cardiac Amyloidosis: Inside Two-Dimensional, Doppler, and Strain Imaging.

Authors:  Dalia Di Nunzio; Antonino Recupero; Cesare de Gregorio; Concetta Zito; Scipione Carerj; Gianluca Di Bella
Journal:  Curr Cardiol Rep       Date:  2019-02-12       Impact factor: 2.931

Review 4.  Strain, strain rate, torsion, and twist: echocardiographic evaluation.

Authors:  Anders Opdahl; Thomas Helle-Valle; Helge Skulstad; Otto A Smiseth
Journal:  Curr Cardiol Rep       Date:  2015-03       Impact factor: 2.931

Review 5.  Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review.

Authors:  Frederick L Ruberg; Martha Grogan; Mazen Hanna; Jeffery W Kelly; Mathew S Maurer
Journal:  J Am Coll Cardiol       Date:  2019-06-11       Impact factor: 24.094

6.  ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging.

Authors:  Sharmila Dorbala; Yukio Ando; Sabahat Bokhari; Angela Dispenzieri; Rodney H Falk; Victor A Ferrari; Marianna Fontana; Olivier Gheysens; Julian D Gillmore; Andor W J M Glaudemans; Mazen A Hanna; Bouke P C Hazenberg; Arnt V Kristen; Raymond Y Kwong; Mathew S Maurer; Giampaolo Merlini; Edward J Miller; James C Moon; Venkatesh L Murthy; C Cristina Quarta; Claudio Rapezzi; Frederick L Ruberg; Sanjiv J Shah; Riemer H J A Slart; Hein J Verberne; Jamieson M Bourque
Journal:  J Nucl Cardiol       Date:  2019-12       Impact factor: 5.952

7.  Transthyretin cardiac amyloid and aortic stenosis in the elderly, the role of nuclear imaging.

Authors:  Elisa Merli; Eleonora Del Giudice; Athanassios Antonopoulos; Gianadrea Amadei; Elisabetta Varani
Journal:  Int J Cardiovasc Imaging       Date:  2017-02-02       Impact factor: 2.357

8.  State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis.

Authors:  Vasvi Singh; Rodney Falk; Marcelo F Di Carli; Marie Kijewski; Claudio Rapezzi; Sharmila Dorbala
Journal:  J Nucl Cardiol       Date:  2018-12-19       Impact factor: 5.952

9.  A histopathologic schema to quantify the burden of cardiac amyloidosis: Relationship with survival and echocardiographic parameters.

Authors:  Priya Mehta; David B Chapel; Neha Goyal; Dong Bo Yu; Victor Mor-Avi; Akhil Narang; Karima Addetia; Nitasha Sarswat; Roberto M Lang; Aliya N Husain; Amit R Patel
Journal:  Echocardiography       Date:  2018-12-28       Impact factor: 1.724

Review 10.  Wild-Type Transthyretin Cardiac Amyloidosis: Novel Insights From Advanced Imaging.

Authors:  David L Narotsky; Adam Castano; Jonathan W Weinsaft; Sabahat Bokhari; Mathew S Maurer
Journal:  Can J Cardiol       Date:  2016-05-13       Impact factor: 5.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.